AbCellera Biologics (ABCL) Stock Price, News & Analysis

Company Overview

AbCellera Biologics Inc. is a biotechnology company that develops technologies for the discovery and development of antibody medicines. Its platform combines high-throughput screening, single-cell analysis, microfluidics, data science and machine learning to identify antibodies with potential therapeutic applications.

The company works with pharmaceutical and biotechnology partners worldwide, helping them discover and advance antibody candidates for areas such as cancer, infectious diseases, autoimmune disorders and other medical conditions. AbCellera provides access to its discovery platform, laboratory capabilities and scientific expertise, while also pursuing selected internal drug development programs.

Founded in 2012 and headquartered in Vancouver, British Columbia, AbCellera has supported antibody discovery programs for partners in multiple global markets. Its technology contributed to the discovery of bamlanivimab, an antibody treatment developed with Eli Lilly for COVID-19. Carl Hansen, one of the company’s co-founders, serves as its president and chief executive officer.

Key Stats

• Today's Range: $11.69 to $12.86
• 50-Day Range: $6.53 to $14.82
• 52-Week Range: $2.74 to $15.02
• Volume: 5.76 million shs
• Average Volume: 5.59 million shs
• Market Capitalization: $3.89 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.89
• Consensus Rating: Moderate Buy

AbCellera Biologics Stock Analysis - MarketRank™

AbCellera Biologics scored higher than 37% of companies evaluated by MarketBeat, and ranked 705th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for AbCellera Biologics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

AbCellera Biologics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.69) to ($0.82) per share.

Price to Book Value per Share Ratio

AbCellera Biologics has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.80% of the float of AbCellera Biologics has been sold short.

Short Interest Ratio / Days to Cover

AbCellera Biologics has a short interest ratio ("days to cover") of 5.98.

Change versus previous month

Short interest in AbCellera Biologics has recently decreased by 4.22%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AbCellera Biologics does not currently pay a dividend.

Dividend Growth

AbCellera Biologics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.49

News Sentiment

AbCellera Biologics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for AbCellera Biologics this week, compared to 4 articles on an average week.

Search Interest

Only 14 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

5 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AbCellera Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.40% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/15/2026
• Next Earnings (Confirmed): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ABCL
• CIK: 1703057
• Web: www.abcellera.com
• Phone: 604-559-9005
• Fax: N/A
• Employees: 562
• Year Founded: 2012

Price Target and Rating

• Average Price Target for AbCellera Biologics: $13.89
• High Price Target: $30.00
• Low Price Target: $4.00
• Potential Upside/Downside: +9.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$146.41 million
• Net Margins: -248.83%
• Pretax Margin: -297.36%
• Return on Equity: -17.49%
• Return on Assets: -12.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.77
• Quick Ratio: 12.77

Sales & Book Value

• Annual Sales: $66.17 million
• Price / Sales: 58.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.23 per share
• Price / Book: 3.93

Miscellaneous

• Outstanding Shares: 306,611,000
• Free Float: 219,533,000
• Market Cap: $3.89 billion
• Optionable: Optionable
• Beta: 1.41